Jonathan Wolleben
Stock Analyst at Citizens
(4.56)
# 227
Out of 5,072 analysts
242
Total ratings
53.97%
Success rate
22.41%
Average return
Main Sectors:
Stocks Rated by Jonathan Wolleben
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SGMT Sagimet Biosciences | Maintains: Market Outperform | $33 → $35 | $7.22 | +384.76% | 9 | Nov 14, 2025 | |
| SVRA Savara | Maintains: Market Outperform | $11 → $10 | $6.29 | +58.98% | 10 | Nov 13, 2025 | |
| SPRB Spruce Biosciences | Maintains: Market Outperform | $254 → $259 | $100.00 | +159.00% | 9 | Nov 11, 2025 | |
| KALV KalVista Pharmaceuticals | Maintains: Market Outperform | $29 → $28 | $14.44 | +93.97% | 6 | Nov 11, 2025 | |
| PTGX Protagonist Therapeutics | Maintains: Market Outperform | $69 → $102 | $90.00 | +13.33% | 13 | Nov 7, 2025 | |
| CRNX Crinetics Pharmaceuticals | Maintains: Market Outperform | $143 → $108 | $45.63 | +136.69% | 17 | Nov 7, 2025 | |
| ALT Altimmune | Maintains: Market Outperform | $15 → $14 | $5.26 | +166.16% | 14 | Nov 7, 2025 | |
| BCRX BioCryst Pharmaceuticals | Maintains: Market Outperform | $27 → $25 | $7.18 | +248.19% | 10 | Nov 5, 2025 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Market Outperform | $485 → $527 | $596.98 | -11.72% | 14 | Nov 5, 2025 | |
| MIRM Mirum Pharmaceuticals | Maintains: Market Outperform | $81 → $95 | $72.95 | +30.23% | 12 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Outperform | $20 | $6.22 | +221.80% | 1 | Nov 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $12.65 | - | 4 | Oct 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $20 → $29 | $12.17 | +138.29% | 18 | Oct 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $135 → $142 | $109.15 | +30.10% | 5 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $18 | $3.55 | +407.04% | 13 | Aug 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $55 → $52 | $28.38 | +83.23% | 12 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $9 → $8 | $3.65 | +119.18% | 2 | Aug 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $89 → $87 | $35.81 | +142.95% | 10 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $8 | $2.34 | +241.88% | 8 | Jun 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $21 | $13.06 | +60.80% | 15 | Jun 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $15 | $1.31 | +1,045.04% | 3 | Jun 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $19 | $6.60 | +187.88% | 9 | May 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $75 | $0.41 | +18,192.68% | 11 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Outperform | $38 | $34.49 | +10.18% | 1 | Apr 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $55 → $50 | $42.83 | +16.74% | 1 | Dec 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $90 | $68.80 | +30.81% | 1 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $116.99 | - | 1 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Accumulate | $420 → $485 | $598.87 | -19.01% | 1 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $8 | $0.66 | +1,112.86% | 11 | Apr 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $25 → $24 | $28.25 | -15.04% | 1 | May 12, 2023 |
Sagimet Biosciences
Nov 14, 2025
Maintains: Market Outperform
Price Target: $33 → $35
Current: $7.22
Upside: +384.76%
Savara
Nov 13, 2025
Maintains: Market Outperform
Price Target: $11 → $10
Current: $6.29
Upside: +58.98%
Spruce Biosciences
Nov 11, 2025
Maintains: Market Outperform
Price Target: $254 → $259
Current: $100.00
Upside: +159.00%
KalVista Pharmaceuticals
Nov 11, 2025
Maintains: Market Outperform
Price Target: $29 → $28
Current: $14.44
Upside: +93.97%
Protagonist Therapeutics
Nov 7, 2025
Maintains: Market Outperform
Price Target: $69 → $102
Current: $90.00
Upside: +13.33%
Crinetics Pharmaceuticals
Nov 7, 2025
Maintains: Market Outperform
Price Target: $143 → $108
Current: $45.63
Upside: +136.69%
Altimmune
Nov 7, 2025
Maintains: Market Outperform
Price Target: $15 → $14
Current: $5.26
Upside: +166.16%
BioCryst Pharmaceuticals
Nov 5, 2025
Maintains: Market Outperform
Price Target: $27 → $25
Current: $7.18
Upside: +248.19%
Madrigal Pharmaceuticals
Nov 5, 2025
Maintains: Market Outperform
Price Target: $485 → $527
Current: $596.98
Upside: -11.72%
Mirum Pharmaceuticals
Nov 5, 2025
Maintains: Market Outperform
Price Target: $81 → $95
Current: $72.95
Upside: +30.23%
Nov 3, 2025
Initiates: Market Outperform
Price Target: $20
Current: $6.22
Upside: +221.80%
Oct 15, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $12.65
Upside: -
Oct 1, 2025
Maintains: Market Outperform
Price Target: $20 → $29
Current: $12.17
Upside: +138.29%
Sep 25, 2025
Maintains: Market Outperform
Price Target: $135 → $142
Current: $109.15
Upside: +30.10%
Aug 19, 2025
Reiterates: Market Outperform
Price Target: $18
Current: $3.55
Upside: +407.04%
Aug 13, 2025
Maintains: Market Outperform
Price Target: $55 → $52
Current: $28.38
Upside: +83.23%
Aug 12, 2025
Maintains: Market Outperform
Price Target: $9 → $8
Current: $3.65
Upside: +119.18%
Aug 7, 2025
Maintains: Market Outperform
Price Target: $89 → $87
Current: $35.81
Upside: +142.95%
Jun 27, 2025
Reiterates: Market Outperform
Price Target: $8
Current: $2.34
Upside: +241.88%
Jun 26, 2025
Reiterates: Market Outperform
Price Target: $21
Current: $13.06
Upside: +60.80%
Jun 24, 2025
Reiterates: Market Outperform
Price Target: $15
Current: $1.31
Upside: +1,045.04%
May 23, 2025
Reiterates: Market Outperform
Price Target: $19
Current: $6.60
Upside: +187.88%
May 16, 2025
Reiterates: Market Outperform
Price Target: $75
Current: $0.41
Upside: +18,192.68%
Apr 10, 2025
Initiates: Market Outperform
Price Target: $38
Current: $34.49
Upside: +10.18%
Dec 18, 2024
Maintains: Market Outperform
Price Target: $55 → $50
Current: $42.83
Upside: +16.74%
Dec 16, 2024
Reiterates: Market Outperform
Price Target: $90
Current: $68.80
Upside: +30.81%
Dec 16, 2024
Reiterates: Market Perform
Price Target: n/a
Current: $116.99
Upside: -
Nov 13, 2024
Downgrades: Accumulate
Price Target: $420 → $485
Current: $598.87
Upside: -19.01%
Apr 19, 2024
Reiterates: Market Outperform
Price Target: $8
Current: $0.66
Upside: +1,112.86%
May 12, 2023
Maintains: Outperform
Price Target: $25 → $24
Current: $28.25
Upside: -15.04%